The validation of the predictive value of CK-19 mRNA-positive cells for CNS relapse, however, requires a prospective study with a higher number of patients, a more prolonged follow-up period and further molecular and biological characterization of peripheral blood CK-19 mRNA-positive occult tumor cells. This evidence concerns the gene KRT19 and neoplasm.